Skip to content
Accessibility help
Search NICE…
Skip to content
Menu
Sign in
Guidance
Standards and indicators
Life sciences
British National Formulary (BNF)
British National Formulary for Children (BNFC)
Clinical Knowledge Summaries (CKS)
About
Home
NICE guidance
Awaiting development
Guidance and quality standards
Awaiting development
Skip to filters
Skip to results
Published
In consultation
In development
Awaiting development
Topic selection
Filter (14 active)
Skip to results
Filter by title or keyword
Filter
Area of interest
Area of interest
COVID-19 (9)
Type
(
2 selected
)
Type
Guidance (315)
Quality standard (0)
Guidance programme
(
12 selected
)
Guidance programme
Antimicrobial prescribing guidelines (0)
Cancer service guidelines (0)
Clinical guidelines (0)
Diagnostics guidance (2)
Health technology evaluations (2)
Highly specialised technologies guidance (1)
Interventional procedures guidance (18)
Medical technologies guidance (7)
Medicines practice guidelines (0)
Public health guidelines (0)
Safe staffing guidelines (0)
Social care guidelines (0)
Technology appraisal guidance (287)
Apply filters
Showing 201 to 250 of 315
Type: Guidance
Remove Type: Guidance filter
Type: Quality standard
Remove Type: Quality standard filter
Guidance programme: Technology appraisal guidance
Remove Guidance programme: Technology appraisal guidance filter
Guidance programme: Interventional procedures guidance
Remove Guidance programme: Interventional procedures guidance filter
Guidance programme: Medical technologies guidance
Remove Guidance programme: Medical technologies guidance filter
Guidance programme: Diagnostics guidance
Remove Guidance programme: Diagnostics guidance filter
Guidance programme: Highly specialised technologies guidance
Remove Guidance programme: Highly specialised technologies guidance filter
Guidance programme: Antimicrobial prescribing guidelines
Remove Guidance programme: Antimicrobial prescribing guidelines filter
Guidance programme: Cancer service guidelines
Remove Guidance programme: Cancer service guidelines filter
Guidance programme: Clinical guidelines
Remove Guidance programme: Clinical guidelines filter
Guidance programme: Medicines practice guidelines
Remove Guidance programme: Medicines practice guidelines filter
Guidance programme: Public health guidelines
Remove Guidance programme: Public health guidelines filter
Guidance programme: Safe staffing guidelines
Remove Guidance programme: Safe staffing guidelines filter
Guidance programme: Social care guidelines
Remove Guidance programme: Social care guidelines filter
Guidance and quality standards awaiting development
Title
Type
Pembrolizumab with olaparib and chemoradiation for previously untreated limited-stage ID6412 small-cell lung cancer TS ID 11975
Technology appraisal guidance
Pembrolizumab with stereotactic body radiotherapy for treating unresected stage 1 or 2 non-small-cell lung cancer [ID6149]
Technology appraisal guidance
Pembrolizumab–vibostolimab for untreated metastatic non-small-cell lung cancer [ID6365]
Technology appraisal guidance
Perampanel for adjunctive treatment of partial onset or generalised tonic-clonic seizures in children aged below 12 years with epilepsy ID1587
Technology appraisal guidance
Phrenic nerve pacing for congenital central hypoventilation syndrome
Interventional procedures guidance
Phrenic nerve pacing for ventilator-dependent high cervical spinal cord injury
Interventional procedures guidance
Plinabulin with docetaxel for previously treated advanced non-small-cell lung cancer [ID3895]
Technology appraisal guidance
PLX-PAD for treating muscle injury after arthroplasty for hip fracture in people 60 to 90 years [ID3989]
Technology appraisal guidance
Prostate cancer (hormone relapsed, homologous recombination deficiency, metastatic) – rucaparib (after 1 therapy) [ID6127]
Technology appraisal guidance
Pulsed Field Ablation (PFA) for atrial fibrillation
Interventional procedures guidance
PXT3003 for treating Charcot-Marie-Tooth disease type 1A in people aged 16 and over TS ID 9130
Technology appraisal guidance
Ranibizumab port delivery system for treating diabetic macular oedema TS ID 10549
Technology appraisal guidance
Ravulizumab for untreated thrombotic microangiopathy after a haematopoietic stem cell transplant in people aged 28 days and over TS ID 10642
Technology appraisal guidance
REGN5458 for treating relapsed or refractory multiple myeloma TS ID 10443
Technology appraisal guidance
Remdesivir for treating COVID 19 [ID3808]
Technology appraisal guidance
Remibrutinib for treating chronic spontaneous urticaria inadequately controlled by H1-antihistamines TS ID 11903
Technology appraisal guidance
Resmetirom for treating non-alcoholic steatohepatitis and liver fibrosis TS ID 11905
Technology appraisal guidance
Retifanlimab with chemotherapy for previously untreated metastatic non-small-cell lung cancer ID 6436
Technology appraisal guidance
Rilzabrutinib for treating persistent or chronic immune thrombocytopenia in people aged 12 and over [ID6395]
Technology appraisal guidance
Rivaroxaban for treating chronic heart failure [ID1462]
Technology appraisal guidance
Rivoceranib for treating unresectable or advanced gastric or gastro-oesophageal junction cancer after 2 or more therapies [ID3819]
Technology appraisal guidance
Rucaparib for treating hormone-relapsed metastatic prostate cancer with homologous recombination deficiency after 1 therapy TS ID 10764
Technology appraisal guidance
Rucaparib with nivolumab for maintenance treatment of platinum-sensitive advanced ovarian, fallopian tube or peritoneal cancer after 1 therapy TS ID 10763
Technology appraisal guidance
Ruxolitinib for treating acute graft-versus-host disease after allogeneic stem cell transplant in people 28 days to 17 years [ID6410]
Technology appraisal guidance
Sabatolimab with azacitidine for untreated high-risk myelodysplastic syndromes [ID3996]
Technology appraisal guidance
Sabizabulin for treating COVID 19 TS ID 11814
Technology appraisal guidance
Sacituzumab govitecan for treating unresectable metastatic urothelial cancer [ID6150]
Technology appraisal guidance
Sacituzumab govitecan for untreated PD-L1-negative triple-negative advanced breast cancer ID6433
Technology appraisal guidance
Sarilumab for treating polyarticular or oligoarticular juvenile idiopathic arthritis in people 2 to 17 years TS ID 10237
Technology appraisal guidance
Sarizotan for the treatment of respiratory symptoms associated with Rett syndrome [ID1506]
Technology appraisal guidance
Sebetralstat for treating acute attacks of hereditary angioedema in people aged 12 and over TS ID 11846
Technology appraisal guidance
Selinexor for treating unresectable dedifferentiated advanced liposarcoma [ID3825]
Technology appraisal guidance
Selpercatinib for treating advanced thyroid cancer with RET alterations (MA review of TA742) [ID6288]
Technology appraisal guidance
Selpercatinib for treating RET fusion-positive advanced solid tumours in people aged 12 and over with no other treatment options TS ID 11850
Technology appraisal guidance
Semaglutide for preventing major cardiovascular events in people with cardiovascular disease and living with overweight or obesity ID6441
Technology appraisal guidance
Semaglutide for treating non-alcoholic steatohepatitis with significant liver fibrosis TS ID 11945
Technology appraisal guidance
Semaglutide for treating type 2 diabetes (ID1450)
Technology appraisal guidance
Serplulimab with chemotherapy for untreated extensive-stage small-cell lung cancer [ID6346]
Technology appraisal guidance
Setmelanotide for treating acquired hypothalamic obesity in people 4 years and older TSID 11995
Technology appraisal guidance
Setmelanotide for treating obesity caused by a rare genetic disorder in children aged 2 to 5 TS ID 11827
Technology appraisal guidance
Single-step scaffold insertion for repairing symptomatic chondral knee defects
Interventional procedures guidance
Sirolimus-eluting collagen implant for creating vascular access for haemodialysis in end-stage kidney disease TS ID 9147
Technology appraisal guidance
Sodium zirconium cyclosilicate for the first line treatment of hyperkalaemia [ID6439]
Technology appraisal guidance
Sotagliflozin for treating type 2 diabetes [ID1657]
Technology appraisal guidance
Sparsentan for treating focal segmental glomerulosclerosis in people 8 years and over [ID3955]
Technology appraisal guidance
Speedboat Inject for endoscopic submucosal dissection of lower gastrointestinal lesions
Medical technologies guidance
STG320 for treating allergic rhinitis or rhinoconjunctivitis caused by house dust mites [ID1278]
Technology appraisal guidance
STS101 for treating acute migraine TS ID 11782
Technology appraisal guidance
Subcutaneous efgartigmod with recombinant human hyaluronidase PH20 for treating chronic inflammatory demyelinating polyneuropathy ID6409
Technology appraisal guidance
Subcutaneous efgartigmod with recombinant human hyaluronidase PH20 for treating primary immune thrombocytopenia TS ID 11977
Technology appraisal guidance
Previous page
1
…
3
4
Current page
5
6
7
Page
5
of
7
Next page
Results per page
10
25
50
All
Back to top